Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma
Adrien Daniel, Louis Terriou(Centre Hospitalier Universitaire de Lille), Florence Lachenal, Camille Ravaiau(Université d'Angers), Charles Herbaux(Centre Hospitalier Universitaire de Lille), Mathieu Wémeau(Inserm), Éléonore Kaphan(Hôpital Saint-Louis), Olivier Tournilhac, Jean‐Baptiste Bossard(Centre Hospitalier Universitaire de Lille), S. Guillet(Assistance Publique – Hôpitaux de Paris), Bertrand Godeau(Université Paris-Est Créteil), Adeline Piérache(Université de Lille), Doriane Cavalieri(University of Clermont Auvergne), David Ghez(Hôpital Necker-Enfants Malades), Mélanie Roriz(Centre Hospitalier Agen - Nérac), Regny Caroline(Ziauddin Hospital), Marc Michel(Université Paris-Est Créteil), Hélène Demarquette(Ikerbasque)
Cited by 8
Related Papers
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*
|British Journal of Dermatology|2021|414
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309